<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03403452</url>
  </required_header>
  <id_info>
    <org_study_id>APAMCRC</org_study_id>
    <nct_id>NCT03403452</nct_id>
  </id_info>
  <brief_title>Apatinib in the Treatment of Metastatic Colorectal Cancer</brief_title>
  <official_title>A Exploratory Clinical Trial Study on Apatinib in the Treatment of Metastatic Colorectal Cancer Who Have Progressed After Standard Second Line Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an Exploratory Clinical Trial Study on Apatinib in the Treatment of Metastatic
      Colorectal Cancer Who Have Progressed after Standard Second Line Therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS（progress free survival）</measure>
    <time_frame>From assignment of the first subject to 3 months later after the last participant is recruited</time_frame>
    <description>PFS was defined as the time from assignment to disease progression radiological/clinical or death due to any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS（overall survival）</measure>
    <time_frame>From assignment of the first subject until 30 death events observed, up to 2 years</time_frame>
    <description>OS is defined as the time from date of assignment to death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR（objective response rate）</measure>
    <time_frame>From assignment of the first subject to 3 months later after the last participant is recruited</time_frame>
    <description>The percentage of subjects with total number of Complete Response (CR) + total number of Partial Response (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR（disease control rate)</measure>
    <time_frame>From assignment of the first subject to 3 months later after the last participant is recruited</time_frame>
    <description>DCR is defined as the percentage of subjects whose best response was not Progressive Disease (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST) (= total number of Complete Response (CR) + total number of Partial Response (PR) + total number of Stable Disease (SD)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>arm for Apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg,p.o.,qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>500 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.</description>
    <arm_group_label>arm for Apatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 and ≤ 80 years of age

          -  Histological confirmed advanced or metastatic colorectal cancer，at least one
             measurable lesion, larger than 10 mm in diameter by spiral CT

          -  Have failed for ≥ 2 lines of chemotherapy and/or targeted therapy

          -  Life expectancy of more than 3 months

          -  ECOG performance scale 0～1

          -  Duration from the last therapy is more than 4 weeks for operation, radiotherapy or
             cytotoxic agents

          -  Adequate hepatic, renal, heart, and hematologic functions (platelets &gt; 80 ×10^9/L,
             neutrophil &gt; 1.5 × 10^9/L, serum creatinine ≤ 1×upper limit of normal(ULN), bilirubin
             &lt; 1.5 ULN, and serum transaminase ≤ 2.0× ULN)

          -  Child bearing potential, a negative urine or serum pregnancy test result before
             initiating apatinib, must agree and commit to the use of a reliable method of birth
             control for the duration of the study and for 8 weeks after the last dose of test
             article. Male: All subjects who are not surgically sterile or postmenopausal must
             agree and commit to the use of a reliable method of birth control for the duration of
             the study and for 8 weeks after the last dose of test article.

          -  Signed and dated informed consent. Willingness and ability to comply with scheduled
             visits, treatment plans, laboratory tests, and other study procedure.

        Exclusion Criteria:

          -  Prior VEGFR inhibitor treatment within 2 weeks

          -  History of other malignancies within 5 years except cured basal cell carcinoma of skin
             and carcinoma in-situ of uterine cervix

          -  Preexisting uncontrolled hypertension defined as more than 140/90 mmHg despite using
             single medical therapy

          -  More than class I (NCI CTCAE 3.0 ) myocardial ischemia, arrhythmia(including QTcF:male
             ≥ 450 ms, female ≥ 470 ms), or cardiac insufficiency myocardial ischemia, arrhythmia,
             or cardiac insufficiency

          -  Pregnant or lactating women

          -  Before or at the same time any, second malignancies except cured basal cell carcinoma
             of skin and carcinoma in-situ of uterine cervix

          -  URT: urine protein ≥ (++)and &gt; 1.0 g of 24 h

          -  PT, APTT, TT, Fbg abnormal, having hemorrhagic tendency or receiving the therapy of
             thrombolysis or anticoagulation

          -  Certain possibility of gastric or intestine hemorrhage
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianmin Xu, PhD</last_name>
    <phone>+86-13501984869</phone>
    <email>xujmin@aiiyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of General Surgery, Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jianmin xu, professor</last_name>
      <phone>008613501984869</phone>
      <email>xujmin@yahoo.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>qi lin, doctor</last_name>
      <phone>008615021519618</phone>
      <email>lin777qi@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2018</study_first_submitted>
  <study_first_submitted_qc>January 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2018</study_first_posted>
  <last_update_submitted>January 11, 2018</last_update_submitted>
  <last_update_submitted_qc>January 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xu jianmin</investigator_full_name>
    <investigator_title>Director of colorectal surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

